Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch

Microbiome pioneer Seres Therapeutics faced numerous setbacks throughout the years in numerous fields, most prominently for its lead program in C. difficile infections. But the biotech has plotted a comeback after a major flop six years ago, and is confident enough to start seeking cash ahead of a possible market launch.